TruthArchive.ai - Related Video Feed

So once I knew it was safe, then I started using it, and then I found it worked. And then, yeah, all in all, I treated well over 6,000 patients, and everybody that got early treatment stayed out of the hospital. I also had patients come in that were really sick in the second week. And that was such a learning experience for me because normally if somebody walked into my office with an oxygen saturation in the low 80s, I would call an ambulance. But I had patients who were refusing to go to the hospital, and I had to give them the option to possibly die in my office, which is scary. But we saved them. I mean, we just threw the kitchen sink at him, and we didn't have monoclonal antibodies. So we brought him in every day. We did IV steroids. We did IV antibiotics. We gave him home oxygen. We gave him high dose of ivermectin.

Hello President Trump, I'm Dr. Vladimir Zelenko from Orange County, NY. I've been treating a large number of COVID-19 patients in my community with hydroxychloroquine and zinc to keep them out of hospitals. I recommend starting treatment early for high-risk patients at home, not just in hospitals. This approach has shown positive results with no hospitalizations among the 100 patients I've treated. Thank you for your efforts in saving the nation. God bless you and your family.

There are ongoing clinical trials in France to determine the effectiveness of hydroxychloroquine and other promising drugs, such as azithromycin and antiviral molecules, in treating COVID-19. The Minister of Health has authorized compassionate use of these medications while waiting for the results of these trials. Several studies are currently underway, including one in Montpellier and one in Angers, to assess the efficacy of these drugs when administered early in the disease. The Minister emphasizes the importance of scientific evidence and the need to balance the urgency of research with patient safety. Preliminary results on reducing viral load are expected in the coming days. The Minister is hopeful but emphasizes the importance of scientific rigor in determining the effectiveness of these treatments.

At home, it is recommended to treat viral replication by giving remedies like zinc and hydroxychloroquine, ivermectin, which reduce the spread of the disease. However, the protocol followed was different. No treatment was given until hospitalization, where ventilators and Remdesivir were used. It is known that Remdesivir can be harmful, as it caused side effects in Ebola patients. The drug was manipulated and made standard of care, leading to kidney failure, heart failure, and organ collapse in COVID-19 patients. The deaths during the pandemic were often attributed to kidney failure, which was caused by Remdesivir, not the virus itself.

I worked in a community hospital that cared for marginalized communities during COVID. I convinced the Chairman of the Board to turn the entire hospital into an ICU to handle the expected surge. Meanwhile, I co-founded the FLCCC with Dr. Paul Maric and Dr. Pierre Kory to develop guidelines and protocols. We had great success using the MAF plus protocol, cortisone-like agents, vitamin C, and repurposed drugs like Ivermectin. My hospital's mortality rate was only 4.4%, much lower than average.

Basically, regardless of the disease stage, many people in Maranhão are already receiving chloroquine. The state healthcare system primarily focuses on severe cases, so most of our patients who are hospitalized fall into that category. However, I cannot confirm if all of them are severe cases since I am not a medical professional.

I hope they use hydroxychloroquine and Z Pak with doctor's approval. It's been around for a long time, so why not try it? I want to avoid ventilators because the outcomes are not good. Hydroxychloroquine could be a game-changer if it works. It's their choice to take it, but I recommend trying it. Avoid Z Pak if you have a heart condition. Let's keep people off ventilators and find a better solution.

It's frustrating that effective treatments used globally aren't considered here. A doctor mentioned that many treatments don't work, and with a high mortality rate, there's little to lose by trying new options. Patients often present with severe breathing difficulties and thick mucus in their lungs, visible on X-rays. Proven treatments exist, like high-dose IV vitamin C, which has shown success in trials, but these are often dismissed. Instead, patients are frequently sedated and placed on ventilators. Despite the historical skepticism surrounding vitamin C, it has potential benefits that are overlooked, leaving many to question the current medical approach.

When unable to use nirmatrlviriteonazia due to interaction issues, the REM des Ivir can be used instead. It is recommended to administer it in hospitals early on and ideally before the patient requires oxygen. This helps prevent the progression to severe forms of the condition.

Noninvasive ventilation like CPAP or BiPAP is not being used in some New York City hospitals due to COVID. Patients are quickly put on ventilators, neglecting other treatments. Nurses report patients being left to die without proper care or family support. Ventilators cause lung trauma, with high pressure and sedation protocols. Traditional treatments like hydroxychloroquine, zinc, and vitamins are not being used, despite patient consent being obtained without full understanding.

We discovered that Ivermectin can kill COVID-19 in primate cells. A single dose of the drug stopped the virus from replicating within 48 hours. Human trials are on the horizon, as the drug has been safely used for decades. Repurposing existing drugs like Ivermectin can speed up development by utilizing known safety profiles and administration methods. We are working on determining if these benefits can translate to treating COVID-19 in humans.

This is a report on a nursing home in Texas City that experienced a major COVID-19 outbreak. The nursing home used a treatment approach that included Hydroxychloroquine, a Z Pak, and Zinc for residents showing symptoms. Despite controversy surrounding the use of Hydroxychloroquine, the treatment seemed promising and only one patient has died since. The goal was to treat residents on-site and prevent further spread of the virus. The nursing home staff closely monitored patients and conducted EKG tests to ensure their safety. The decision to pursue this treatment path was made to avoid potential loss of life among residents.

There are studies that suggest increased mortality with hydroxychloroquine, but there are also French studies that show a 50% decrease in deaths with its use. However, there is no significant difference in mortality rates. Some studies, including one from the CHU de Lyon, have shown serious side effects from hydroxychloroquine. Giving hydroxychloroquine to someone with a cardiac condition related to Covid increases the risk of cardiac complications. It not only lacks benefits but also increases the chances of intubation, ventilation, or death by 13%. Thankfully, the prescription of hydroxychloroquine in the community has been banned, which is considered a crucial public health measure that prevented potentially hundreds or even thousands of deaths.

Hello, I'm Dr. Vladimir Zelenko, a family practitioner in New York. I propose early outpatient treatment for moderate to high-risk COVID-19 patients, having successfully treated over 100 without hospitalizations. Hydroxychloroquine, approved for decades and considered safe, was suddenly restricted, leading to patient deaths. I sought alternatives and discovered quercetin, an over-the-counter supplement that helps deliver zinc into cells, similar to hydroxychloroquine. Facing my own terminal illness, I realized the importance of family, compassion, and freedom. This is a battle for our rights and consciousness against tyranny. Civil disobedience is essential; we must resist and protect our freedoms. The Second Amendment safeguards us from oppressive government. We need faith and courage to confront these challenges, relying on a higher power to guide us in this struggle.

In 1970, a Japanese biochemist named Satoshi Omorra discovered a bacterium with intriguing effects against roundworm and shared it with American colleague William Campbell of Merck. Campbell used the bacterium to create ivermectin, released by Merck in 1980. Ivermectin proved extremely effective against river blindness (onchocerciasis), a disease caused by a parasitic worm that affected Central and South America and much of Africa. With ivermectin, river blindness has been largely eliminated in the Americas and greatly reduced in Africa. Billions of doses have been administered; it is listed among the World Health Organization’s essential medicines. Merck’s patent expired in 1996; the drug is cheap to produce, globally available in various formulations, and, at normal dosages, has no important side effects. In 2015, Omurra received the Nobel Prize for Medicine, shared with Campbell. Fast forward to early 2020, when the COVID-19 pandemic spread. Scientists searched for drugs with antiviral activity, and Monash University in Australia conducted a literature search that found ivermectin had shown activity against Zika, West Nile, and influenza. They performed experiments and found that ivermectin displays remarkable activity against SARS-CoV-2 in vitro, reporting a 5,000-fold reduction in viral levels after a single treatment without cytotoxicity, and proposed a mechanism for this effect. Around the same time, two American scientists noted that ivermectin was used as prophylaxis against river blindness in Africa and examined whether widespread ivermectin prophylaxis correlated with COVID-19 rates. They found that countries with extensive ivermectin prophylaxis had significantly lower COVID-19 rates. In Miami, Dr. Jean Jacques Reiter, a critical care and pulmonary specialist, treated COVID-19 patients with ivermectin after being urged by a patient’s son. He reported rapid improvement: the patient’s FiO2 requirements declined within 48 hours, and she was discharged within about a week. Reiter treated many patients with ivermectin and published a June 2020 preprint; he later testified before a Senate committee about his experiences. He stated that among hundreds of outpatients treated by his team, only two were admitted to the hospital; neither died or required intubation. Uncontrolled studies on ivermectin as prophylaxis and treatment circulated globally. A daughter described a care-home incident in Ontario, where residents on a floor receiving high-dose ivermectin for scabies reportedly had no COVID-19 infections among residents, even as staff on that floor became infected. In New York, Pierre Corry teamed with Reiter and Paul Merrick to form the Frontline COVID-19 Critical Care Alliance (FLCCC). In October 2020, the FLCCC released the Eye Mask Plus protocol, centering on ivermectin for prevention and treatment, and published a meta-analysis reviewing nine studies on prophylaxis and 12 studies on treatment, including seven randomized trials, all showing ivermectin’s superiority to controls. They presented figures showing reduced mortality and case rates associated with ivermectin use in various regions, including Peru, Mexico (Chiapas), and Argentina (healthcare workers). On December 8, 2020, FLCCC members appeared before a Senate subcommittee, with testimony claiming mountains of data showing ivermectin’s miraculous effectiveness and requesting the NIH to review their data. The transcript asserts widespread suppression of ivermectin information by mainstream media (New York Times, AP), big tech (YouTube, Twitter, Facebook), and the NIH. It alleges the NIH COVID-19 treatment guidelines panel, established in April 2020, largely recommended against early treatment and promoted remdesivir instead, even though remdesivir’s mortality impact was unproven and the World Health Organization advised against its use for improving survival. The panel’s treatment recommendations (as of 01/03/2021) are cited, highlighting monoclonal antibodies for early patients and no other treatments, except for remdesivir for deteriorating patients. Fauci publicly touted remdesivir’s endpoint as time to recovery, with the primary endpoint reportedly changed mid-trial from mortality to time to recovery, raising concerns about impartiality. The transcript traces remdesivir's production by Gilead Sciences and notes financial ties: seven panel members disclosed funding from Gilead; two of the three panel chairs received Gilead support, and Clifford Lane (one co-author on a remdesivir study) was closely connected to the study, with undisclosed ties among other authors. It argues these ties could impact decision-making and bias toward remdesivir over cheaper, repurposed drugs like ivermectin. The narrative then contrasts the U.S. approach with Uttar Pradesh, India, which authorized ivermectin as prophylaxis and treatment in August 2020. In January 2021, Uttar Pradesh reported near-zero COVID-19 deaths, while the United States faced ongoing high mortality, suggesting potential differential outcomes if ivermectin had been broadly authorized. The closing remarks emphasize the suffering caused by COVID-19 and its broad impacts on families and society.

North American science spent 15 years researching how to respond to a future coronavirus pandemic after the original SARS CoV-one outbreak in 2002-2003. By 2015-2016, research showed that Ivermectin and Hydroxychloroquine were effective antiviral and immune modulatory treatments. The US military's research arm, DARPA, recommended Ivermectin as the top choice for a coronavirus pandemic and shared this information with the CDC. These medications had been proven safe for humans and had been used for several decades. They were ready to be used in the event of a future pandemic.

Dr. Oz discussed the coronavirus outbreak, referencing South Korea's successful strategy of aggressive, early action, strict testing, and quarantining. He suggests focusing on problem areas instead of broad measures that could cause more harm. While vaccines are 15 months out, repurposing existing drugs for HIV, Ebola, and malaria could slow the virus's growth, especially for high-risk healthcare workers. Chloroquine, an old malaria drug, may help. Oz highlights public-private partnerships advancing treatments for virus complications. He also emphasized "digital vaccines," using technology to identify and protect high-risk individuals, with companies like Sharecare, Apple, Google, and Facebook involved. Dr. Oz mentioned using plasma from recovered patients to transfer antibodies to those afflicted, a method used during the Spanish flu and recently in China. He advocates leveraging recovered individuals' antibodies to save lives while pursuing better solutions.

The speaker shares their experience with using hydroxychloroquine, azithromycin, and zinc as a treatment for COVID-19. They mention informing the President of the United States about their protocol and how it was effective in saving lives. However, they criticize Governor Cuomo for blocking access to hydroxychloroquine, leading to their patients dying again. They then discuss finding a substitute called Quercetin, along with vitamin C, that delivers zinc into cells. They explain how they made this treatment more accessible by combining all the necessary ingredients into one pill. They emphasize the importance of early intervention and mention the potential benefits of the treatment for other viruses like influenza and Ebola. The speaker concludes by discussing the creation of ZStack as a solution to help people.

Honestly, I'll tell you something. All my fellow doctors who were affected by Covid-19 have all taken chloroquine. So, it's hypocritical to say that we need to wait for studies to know what to do. I believe we should give every possible chance to the patients.

Honestly, I'll tell you something. All my fellow doctors who were affected by Covid-19 have all taken chloroquine. So, it's hypocritical to say that we need to wait for studies to know what to do. I believe we should give every possible chance to the patients.

The dialogue centers on treatments and outcomes for COVID-19, with concerns about what is being used and what might work. One participant remarks on the reluctance to use certain treatments that are successful worldwide, recounting a conversation with a doctor. Another asks what kinds of treatments are being tried, noting that some approaches “are coming out with different things that are in the testing phase.” A third person criticizes a platform they believe “kills more people than actually save,” and another agrees that “they don’t work anyway,” questioning the harm in trying alternatives when current efforts aren’t effective. A key exchange discusses expectations for patient survival. One person says, “I don’t expect any of these people to survive. Ninety percent of them would die,” while another adds that if patients are “already dying anyway,” it may be reasonable to try additional measures rather than do nothing. There is debate about whether trying unproven treatments is appropriate; one participant notes that without a scientific basis, extra attempts can make patients worse, while another concedes that they would try anything to save their life. The conversation then shifts to clinical presentations and treatment strategies. With COVID patients who cannot breathe, X-rays show “the lungs are white,” indicating affected lungs with very thick, white secretions. The question arises of what “white lung” means—whether it is mucus and coating that fill the lungs and impede oxygen transfer. In response, the discussion distinguishes between early-stage treatments (like hydroxychloroquine and zinc) and later-stage interventions. It is stated that once lungs are severely affected, certain proven treatments exist that have passed trials in Asia through Dr. Chang, described as a US-board-certified physician. Specifically, extremely high-dose IV vitamin C is claimed to be successful in treating patients, providing the lungs with antioxidant support to help expel the infection, alongside IV antibiotics to treat the infection while avoiding reliance on ventilation and sedation. There is a contrast drawn between approaches in different regions. The dialogue notes that high-dose IV vitamin C has passed three trials in Asia and is reported as effective, while in the speaker’s locale, there is hesitation or reluctance to adopt this method. The discussion ends with a remark about how some people might attribute success to “good genes,” implying a belief that genetics may influence susceptibility or outcomes, though this is stated rather than argued as a scientific conclusion. Overall, the conversation emphasizes that several participants are wary of conventional treatments, advocate for exploring high-dose IV vitamin C as a therapeutic option, and describe the characteristic radiographic and clinical features of severe COVID-19 lung involvement.

North American science spent 15 years researching how to respond to a potential coronavirus pandemic after the original SARS CoV-one outbreak in 2002-2003. By 2015-2016, it was known that Ivermectin and hydroxychloroquine were effective antiviral and immune modulatory treatments. DARPA, the American Research Arm of the U.S. Military, recommended Ivermectin to the CDC as the top product to use in a coronavirus pandemic. These medications had been proven safe for humans and had been used for several decades. So, when the next pandemic hit, North America had Ivermectin and hydroxychloroquine ready for use.

Once it was determined to be safe, the speaker began using a treatment and found that it worked. Over 6,000 patients were treated, and those who received early treatment avoided hospitalization. Some patients came in very sick in their second week, with oxygen saturation in the low 80s, refusing to go to the hospital. The speaker's office offered them the option to possibly die there. They treated these patients with IV steroids, IV antibiotics, home oxygen, and high doses of ivermectin, without using monoclonal antibodies, and the patients were saved.

During COVID, I traveled the country and saw many undiagnosed diseases that could have been treated early, but resulted in COVID deaths. I also witnessed the deterioration of our health system in rural areas, where access to healthcare is limited. The hub and spoke model, designed to get very sick people into regional medical centers, was overwhelmed. COVID highlighted issues with chronic disease management. Similar to early HIV treatment, we initially only treated symptomatic individuals, which was just the tip of the iceberg. When we started finding and treating asymptomatic individuals early, before they showed disease, they could thrive.

Dr. Vladimir Zelenko suggests initiating early treatment for moderate to high-risk COVID-19 patients in the outpatient setting, reporting positive results. He mentions the FDA approval of Hydroxychloroquine for various conditions and questions why it was blocked. He then discusses his search for an alternative, finding Quercetin and vitamin C as a substitute for delivering zinc into cells. Dr. Zelenko emphasizes the importance of faith and freedom, advocating for civil disobedience and resistance against potential government overreach. He concludes by highlighting the need for a mature faith in God to overcome fear and uncertainty.